BRD3731 is a potent, selective GSK3β inhibitor with IC50 of 15 nM, 14-fold selectivity for GSK3β over GSK3α (IC50=215 nM).

BRD2879 (BRD-2879) is a potent, selective inhibitor of IDH1-R132H mutant with IC50 of 50 nM, inhibits cell-based production of R-2HG with EC50 of 0.3 uM.

BRD1991 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity..

BRD1652 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 0.4 nM/4 nM for GSK3α/GSK3β respectively.

BRD1240 is a small-molecule probe that can suppress V-ATPase function, inhibits lysosomal acidification and blocks the maturation of autophagosomes to autolysosomes.

BRD1172 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 3 nM/10 nM for GSK3α/GSK3β, respectively..

BRD10330 (BRD-10330) is a small molecule that upregulates IL-10 production in BMDCs.

BRD0209 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 19 nM/5 nM for GSK3α/GSK3β respectively.

BRD 9876 is an ATP- and ADP-competitive Eg5 (kinesin-5) inhibitor with Ki of 4 nM, selectively inhibits microtubule-bound Eg5 and inhibits multiple myeloma cell growth (IC50=2.2 uM).

BRD 8899 is a potent and selective inhibitor of the serine/threonine kinase STK33 with IC50 of 0.11 nM (25 uM ATP).

BRD 8430 is a potent, selective class I HDAC inhibitor (HDAC1>2 >3) with IC50 of 69 nM/560/1300 nM for HDAC1/2/3, respectively.

BRD 8184 is a potent, selective HDAC6 inhibitor with IC50 of 8 nM, weakly inhibits HDAC2 and HDAC8 (IC50=0.34 and 1.33 uM),has no activity for HDAC4 (IC50>30 uM)..

BRD 0476 (ML187) is a selective, moderate inhibitor of ubiquitin-specific peptidase 9X (USP9X), inhibits pancreatic β-cell apoptosis that inhibits IFN-γ-induced JAK2 and STAT1 signaling to promote β-cell survival.

Bragsin1 (Bragsin 1) is a specific inhibitor of the ArfGEF BRAG2, affects the trans-Golgi network in a BRAG2- and Arf-dependent manner in cells (IC50=3 uM).

Bradykinin is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions.

BRACO-19 is a potent small molecule Telomerase inhibitor (IC50=115 nM) that inhibits expression of human telomerase reverse transcriptase (hTERT).

BR111 is a potent, highly selective and orally active antagonist of complement C3a receptor (C3aR) with IC50 of 85 ± 40  nM (inhibition of hC3a induced Ca2+ release on human macrophages).

BR103 is a potent, metabolically stable and highly selective small molecule agonist of complement C3a receptor (C3aR) with EC50 of 22 ± 8  nM.

BR101549 (BR-101549) is a novel PPARγ non-TZD agonist with EC50 of 1.73 uM (Amax 120%)..

BQU-082 is a novel potent small GTPase Ral (Ras-like) inhibitor with IC50 of 1.7 uM, displays a dose dependent effect on RalA and RalB activity in H2122 spheroids using the common RalBP1 pull-down assay..

BPR1K653 is a novel potent Aurora kinase inhibitor that inhibits Aurora-A and Aurora-B with IC50 of 24 nM and 45 nM, respectively.

BPR1J373 is a potent, orally available multitargeted kinase inhibitor, potently inhibits FLT3, c-KIT, VEGFR1-3, Aurora A, PDGFRα, PDGFRβ, RET, and SRC with IC50 values of <100 nM.

BPO-27 racemate is a potent CFTR inhibitor with an IC50 of 8 nM.

BPN-15606 (BPN15606) is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 by SHSY5Y neuroblastoma cells with IC50 of 7 nM.

BPK-29 is a covalent, specific small molecule that disrupts NR0B1 protein complexes and impairs the anchorage-independent growth of KEAP1-mutant cancer cells.

BPIPP is an inhibitor of GC-C (guanylyl cyclase type C) that inhibits stimulation of guanylyl cyclase and adenylyl cyclase, suppresses cGMP accumulation in a variety of cell lines (IC50=3.4-11.2 uM).

Box5 is a Wnt5a-derived N-butyloxycarbonyl hexapeptide (t-Boc-Met-Asp-Gly-Cys-Glu-Leu), acts as an Wnt5a antagonist.

Bosentan is an endothelin (ET) receptors antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.

Bosentan is a competitive and dual antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors.

Boldenone undecylenate(Equipoise) is a synthetic steroid which has a similar effect as the natural steroid testosterone; it is frequently used in veterinary medicine, though it is also used in humans.